Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Ariana Grande says Eternal Sunshine 2026 tour will be her last for a 'long, long time': 'One last hurrah' - 2Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts
- 3Gulf of Mexico oil spill spread hundreds of miles, killed wildlife and polluted Mexican reserves
- 4Watch South Korean startup Innospace attempt its 1st-ever orbital launch today
- 5Thousands of small fish defy gravity to climb Congo waterfall
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- Grasping the Commencement of Criminal Cases: An Extensive Outline
- Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
- McDonald's is bringing two 'KPop Demon Hunters' meals to McDonald's. Here's what they include and when they launch.
- IVE 2026 'Show What I Am' Tour: How to get tickets, prices, dates and more
- Tesla plans to expand production at German car plant
- The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
- EU delegation urges China to tighten export controls
